ArticleTurkish journal of ophthalmology2026
Epithelial-Island Corneal Crosslinking in the Treatment of Progressive Keratoconus Patients with Thin Corneas: 2-Year Visual, Refractive, Keratometric, Tomographic, and Aberrometric Outcomes.
Article in Turkish journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the visual, refractive, tomographic, and aberrometric outcomes of epithelial-island corneal collagen crosslinking (CXL) treatment in halting progression in keratoconic eyes with thin corneas. Materials and Methods: We retrospectively reviewed the charts of consecutive patients with advanced keratoconus who had a thinnest corneal thickness (TCT) of <380 μm as measured by anterior segment optic coherence tomography and underwent epithelial-island CXL. The procedure involved tomography-guided customized epithelial debridement, followed by corneal saturation with iso-osmolar and hypo-osmolar riboflavin solutions and ultraviolet-A irradiation (30 min, 3.0 mW/cm Results: The study included 10 eyes of 9 patients with a median age of 29.5 (range, 17-51) years. The median postoperative follow-up time was 24.0 (12.0-108.0) months. The median preoperative TCT was 324.0 (232.0-380.0) μm. Preoperatively, the median CDVA was 1.00 (0.70-1.80) logarithm of the minimum angle of resolution, MR spherical equivalent was -18.00 (-25.00 to -6.00) diopters (D), maximum keratometry value was 84.75 (59.80-99.00) D, vertical coma was -1.068 (-6.428 to 0.613) D, and ECC was 2568 (2021-2750) cells/mm Conclusion: Epithelial-island CXL seems to be an effective alternative treatment modality in halting progression in keratoconic eyes with thin corneas. Further studies with a longer follow-up and a larger sample size would help to establish the long-term safety and efficacy of this treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.